Press Releases

Press Releases

International Vaccine Institute and Technical University of Denmark to strengthen external quality assurance in the face of rising antimicrobial resistance in Asia

IVI and Sweden renew partnership to accelerate vaccines for global public health

IVI to lead critical standard reagents availability for oral cholera vaccine manufacturing to ensure their uniform efficacy and help meet global demand

IVI appoints three new members to its Board of Trustees

IVI to Accelerate Efforts in iNTS Vaccine Development

IVI acquires GCLP certification from Korean Ministry of Food and Drug Safety

IVI Awarded $4.5 Million Grant to Increase Accessibility of Oral Cholera Vaccine

IVI Discusses Expanding Support for Global Collaboration on Vaccine R&D and Delivery with Top Foreign Diplomats in Seoul

IVI-led Consortium Awarded Fleming Fund Regional Grant to Improve Data Sharing in Fight against Antimicrobial Resistance

IVI to help developing countries tackle the spread of infectious diseases by building capacity through vaccinology training in Seoul

IVI acquires supplemental funding for Severe Typhoid in Africa Program (SETA Plus)

IVI Director General Dr. Jerome Kim to join the Human Vaccines Project’s Efforts as One of Four Distinguished Global Leaders to Decode the Human Immune System

Prof. Young Chul Sung, biotech leader, personally donates US$8.4 million to IVI

New push to develop world’s first vaccine against the deadly Strep A bacteria killing hundreds of thousand

IVI-led CAPTURA consortium wins Fleming Fund award for work on antimicrobial resistance (AMR) data across Asia

IVI receives $15.7 million grant to conduct phase III trials of new Vi-DT typhoid conjugate vaccine manufactured by SK bioscience of Korea

‘IVI Forum for Enhancement of Cooperation’ hosted jointly by the Korean Parliamentary Forum for Global Health, and KCDC under MOHW

Vaccine study confirms sensitivity of cholera test

Korean Pediatric Association, IVI, KSC exchange MOU

IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa

CEPI partners with IVI to accelerate development of vaccines against emerging global health threats

Henry Lau joins IVI as Goodwill Ambassador

Nature Communications study addresses MDR typhoid

THSTI, IVI held joint symposium on Nov. 22

‘The Euvichol story’ published in Vaccine

IVI accelerates development of MERS vaccine

IVI’s 18th Vaccinology Course gathers 120 international participants from 19 countries in Seoul September 3-7

KOICA, IVI team up with Mozambican MoH and INS, partners to vaccinate 190,000 people against cholera

IVI acquires $5 million grant to support process development, scale up of typhoid conjugate vaccine with SK Bioscience


Mr. George Bickerstaff elected Chair of IVI Board of Trustees, Dr. Hanna Nohynek Vice-Chair

2018-05-28 08:15
The International Vaccine Institute (IVI) today announced that Mr. George Bickerstaff, currently Vice-Chair and Board member since 2009, has been elected as the new Chair of the Board of Trustees of the Institute and Dr. Hanna Nohynek, a Board member since 2016, has been elected as Vice-Chair of the Board. Both appointments are for three-year terms.

Mr. Bickerstaff is a leader in business and philanthropy, with over 35 years of experience in healthcare and finance. He is currently Managing Director of M.M. Dillon & Co., a private investment bank which he co-founded, and previously held the position of Chief Financial Officer of Novartis Pharma AG. He has also worked at Dun & Bradstreet and General Electric.

Mr. Bickerstaff has served as a member of the board of multiple public, private and global foundations, including Gavi, the Vaccine Alliance. His philanthropic interests have focused on healthcare and child protection, serving on the board of non-profits including International Center for Missing Children and Global Oncology. He is based in New York and holds degrees in business and engineering from Rutgers University.

Commenting on his appointment, Mr. Bickerstaff said “It is a great privilege to assume the chairmanship of the Board of Trustees of IVI, an institution with a noble mission for humanity that I have had the pleasure to serve for many years. I look forward to working with the IVI team, donors and partners to help ensure that the institute can make a greater impact in global health and vaccines.”

Dr. Nohynek, the new Vice-Chair, is currently Chief Medical Officer and Deputy Head of Infectious Diseases Control and Vaccines Unit at the National Institute for Health and Welfare in Finland. A practicing physician and vaccinologist, Dr. Nohynek has served on expert committees evaluating the introduction of pneumococcal conjugate vaccines (PCV) and rotavirus vaccine in Finland, and as a technical advisor to the European Union, IVI, the World Health Organization, Gavi, the Finnish Ministry of Foreign Affairs, and several vaccine manufacturers.

IVI Director General, Dr. Jerome Kim said, "IVI is very pleased to welcome Mr. George Bickerstaff, Chair and Dr. Hanna Nohynek, Vice-Chair, in their new appointments. I am sure they will continue to bring a wealth of expertise and experience to the leadership of the board. Under their guidance, IVI will fulfill its commitment to accelerate vaccine research and development to give vulnerable people everywhere the opportunity to lead healthy and productive lives.”

About International Vaccine Institute (IVI)

The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 30 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS-CoV, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit